Stockholm III trial
The Stockholm III trial is a randomised, multicentre trial, comparing different radiationtherapy courses in primary resectable rectal cancer.
Patients are randomised between one of the following arms:
- Preoperative radiotherapy 5 x 5 Gy with surgery within one week
- Preoperative radiotherapy 5 x 5 Gy with surgery after 4-8 weeks
- Preoperative radiotherapy 25 x 2 Gy with surgery after 4-8 weeks
Inclusion criteria:
Primary resectable, biopsy proven adenocarcinoma of the rectum, without signs of distant metastases where abdominal surgery is planned.
Primary Investigator
Anna Martling
Professor/Senior PhysicianPublikationer
Erlandsson J, Holm T, Pettersson D, et al
Lancet Oncol. 2017 Feb;18(3):336-46
Pettersson D, Cedermark B, Holm T, Radu C, P氓hlman L, Glimelius B, et al
Br J Surg 2010 Apr;97(4):580-7
Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T, Martling A
Br J Surg 2013 Jun;100(7):969-75
Pettersson D, L枚rinc E, Holm T, Iversen H, Cedermark B, Glimelius B, et al
Br J Surg 2015 Jul;102(8):972-8; discussion 978